医药行业周报：GSK靶向疗法达到3期临床主要终点，用于治疗PBC

Investment Rating - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [1][8]. Core Views - The pharmaceutical sector has shown a performance increase of +2.52% as of November 20, 2024, outperforming the CSI 300 index by 2.30 percentage points, ranking 4th among 31 sub-industries in the Shenwan classification [3]. - Notable sub-industry performances include pharmaceutical distribution (+2.23%), medical devices (+2.20%), and medical research outsourcing (+2.12%), while offline pharmacies (+0.54%), vaccines (+0.65%), and hospitals (+1.16%) lagged behind [3]. - GSK's global Phase 3 clinical trial for Linerixibat, aimed at treating pruritus associated with primary biliary cholangitis (PBC), has achieved positive topline results, indicating its potential as an oral IBAT inhibitor [4][8]. Summary by Sections Market Performance - As of November 20, 2024, the pharmaceutical sector's performance was +2.52%, surpassing the CSI 300 index by 2.30 percentage points, with the sector ranking 4th among 31 sub-industries [3]. Sub-industry Ratings - The report highlights the performance of various sub-industries, with pharmaceutical distribution, medical devices, and medical research outsourcing leading the gains, while offline pharmacies, vaccines, and hospitals showed lower performance [3]. Company News - Betta Pharmaceuticals received a notice from the National Medical Products Administration regarding the acceptance of its clinical trial application for BPI-452080, targeting tumors related to VHL syndrome [4]. - Jiuzhou Pharmaceutical announced that its subsidiary received GMP certification from the UK Medicines and Healthcare products Regulatory Agency for its tablet production line [4]. - Kehua Bio received a medical device registration certificate for its creatine kinase isoenzyme assay kit from the Shanghai Municipal Medical Products Administration [4]. - Zhongsheng Pharmaceutical reported positive topline analysis data from its Phase II clinical trial for the innovative peptide drug RAY1225, indicating promising efficacy and safety for overweight/obese patients [4].